Impact of CYP3A5 gene polymorphism on efficacy of simvastatin

Open Cardiovascular Medicine Journal

Volumn 8, Issue 1, 2014, Pages 12-17

  Kolovou, Genovefa ^a   Ragia, Georgia ^b   Kolovou, Vana ^a   Mihas, Constantinos ^c   Katsiki, Niki ^d   Vasiliadis, Ioannis ^a   Mavrogeni, Sophie ^a   Vartela, Vassiliki ^a   Tavridou, Anna ^a   Manolopoulos, Vangelis G ^b  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c Kimi General Hospital   (Greece)

^d ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

CYP3A5 gene polymorphism; Low density lipoprotein cholesterol; Simvastatin

Indexed keywords

CYTOCHROME P450 3A5; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; GLUCOSE; LIPID;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DNA POLYMORPHISM; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENETIC PARAMETERS; GENOTYPE; GENOTYPE FREQUENCY; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ALLELE; COLORIMETRY; CONTROLLED STUDY; CYP3A5 GENE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; HETEROZYGOTE; HOMOZYGOTE; LIPID ANALYSIS; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 84899879703     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401408010012     Document Type: Article

References (23)

1. Kolovou GD, Katerina A, Ioannis V, Cokkinos DV. Simvastatin: two decades in a circle. Cardiovasc Ther 2008; 26: 66-78.
2. Kolovou GD, Anagnostopoulou KK, Kostakou PM, Mikhailidis DP. Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs. Curr Med Chem 2009; 16: 4345-60.
3. Anagnostopoulou KK, Kolovou GD, Kostakou PM, et al. Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects. Expert Opin Pharmacother 2007; 8: 2459-63.
4. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 2003; 56: 120-4.
5. Dvorak Z, Pavek P. Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev 2010; 42: 621-35.
6. Hukkanen J. Induction of cytochrome P450 enzymes: a view on human in vivo findings. Expert Rev Clin Pharmacol 2012; 5: 569-85
7. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91.
8. Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics 2009; 10: 1017-24
9. Arvanitidis K, Ragia G, Iordanidou M, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 2007; 21: 419-26.
10. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
11. Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and metaanalysis. Curr Med Res Opin 2011; 27: 1191-210.
12. Kuehl P, Zhang J, Lin Y, et al. Frequency of common CYP3A5 gene variants in healthy Polish newborn infants. Pharmacol Rep 2009; 61: 947-51.
13. Willrich MA, Hirata MH, Genvigir FD, et al. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin Chim Acta 2008; 398: 15-20.
14. Rosales A, Alvear M, Cuevas A, Saavedra N, Zambrano T, Salazar LA. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. Clin Chim Acta 2012; 413: 495-501.
15. Li YP, Zhang LR, Jia M, Hu XJ. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. J Clin Pharmacol 2011; 51: 181-8.
16. Kivistö KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004; 14: 523-5.
17. Shin J, Pauly DF, Pacanowski MA, Langaee T, Frye RF, Johnson JA. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy 2011; 31: 942-50.
18. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007; 47: 87-93.
19. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011; 11: 274-86.
20. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 2012; 8: 371-82.
21. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Apolipoprotein E gene polymorphism and myocardial infarction. Int J Cardiol 2009; 133: 264-5.
22. Zhou Q, Ruan ZR, Jiang B, Yuan H, Zeng S. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms. Pharmazie 2013; 68: 124-8.
23. Gelissen IC, McLachlan AJ. The pharmacogenomics of statins. Pharmacol Res 2013 Dec 21. doi: 10. 1016/j. phrs. 2013. 12. 002. [Epub ahead of print]